| Name | ERK-IN-3 |
|---|---|
| Synonyms |
1H-Imidazole-4-cboxamide, N-[(1S)-2-amino-1-(3-chloro-5-fluorophenyl)ethyl]-1-[5-methyl-2-[(tetrahydro-2H-pyran-4-yl)amino]-4-pyrimidinyl]
ASN007(ERAS 007) ERK-IN-3, 10 mM in DMSO ASN007 ASN007 free base N-[(1S)-2-amino-1-(3-chloro-5-fluorophenyl)ethyl]-1-{5-methyl-2-[(oxan-4-yl)amino]pyrimidin-4-yl}-1H-imidazole-4-cboxamide N-[(1S)-2-amino-1-(3-chloro-5-fluorophenyl)ethyl]-1-[5-methyl-2-(oxan-4-ylamino)pyrimidin-4-yl]imidazole-4-cboxamide ERK1/2,inhibit,ERK,Inhibitor,ERK IN 3,RAS,Extracellul signal regulated kinases,cancer,ERKIN3 (S)-N-(2-Amino-1-(3-chloro-5-fluorophenyl)ethyl)-1-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-cboxamide |
| Description | ERK-IN-3 is a potent and oral inhibitor of ERK. ERK-IN-3 inhibits ERK1/2 with low single-digit nM IC50 values. ERK-IN-3 has the potential to be used to study cancers driven by RAS mutations.[1]. |
|---|---|
| Related Catalog | |
| Target |
ERK1 ERK2 |
| In Vitro | ERK-IN-3 inhibits the phosphorylation of ERK1/2 substrates such as RSK1, FRA1, and Elk1 in various cell lines[1]. ERK-IN-3 showes single-digit nanomolar antiproliferative activity that is selective for MAPK-pathway dependent cancer cell lines[1]. |
| In Vivo | ERK-IN-3 (daily p.o.) inhibits tumor growth in multiple BRAF and KRAS mutant xenograft models in mice and was well tolerated at efficacious doses[1]. |
| References |
| Molecular Formula | C22H25ClFN7O2 |
|---|---|
| Molecular Weight | 473.93 |